The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration

Experimental Neurology

Volumn 184, Issue 1, 2003, Pages 530-535

  Double, K L ^a   Halliday, G M ^a   Henderson, J ^b   Griffiths, F M ^a   Heinemann, T ^c   Riederer, P ^c   Gerlach, M ^c  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Dopamine neurons; Iron; Lisuride; Neuromelanin; Neuroprotection; Parkinson therapy; Rat

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; IRON; LISURIDE; NEUROMELANIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; INJECTION; MALE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SUBSTANTIA NIGRA;

EID: 0344394510     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.08.006     Document Type: Article

References (43)

1. Allain H., Destee A., Petit H., Patay M., Schuck S., Bentue-Ferrer D., Carorzin P. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa montherapy in de novo Parkinson's disease. The French Lisuride study. Eur. Neurol. 44:2000;22-30.
2. Ben-Shachar D., Riederer P., Youdim M.B.H. Iron-melanin interaction and lipid peroxidation implications for Parkinson's disease. J. Neurochem. 57:1991;1609-1614.
3. 18F-dopa PET findings. Mov. Disord. 15:2000;215.
4. Caldwell M., Reymann J., Bentue-Ferrer D., Allain H., Leonard B. The dopamine agonists lisuride and peripededil protect against behavioural and histological changes following 4-vessel occlusion in the rat. Neuropsyschobiology. 34:1996;117-124.
5. Carvey P.M., Pieri S., Ling Z.D. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J. Neural Transm. 104:1997;209-228.
6. Cassarino D., Fall C., Smith T., Bennett J. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the Parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 71:1998;295-301.
7. Chen Y.K., Lin H.C., Liu J.C., Wan F.J. Potent, hydroxyl radical-scavenging effect of apomorphine with iron and dopamine perfusion in rat striatum. Brain Res. 896:2001;165-168.
8. Double K.L., Crocker A. Effects of inactivation of D1 dopamine receptors on stereotypic and thermic responses to quinipirole (LY 171555). Neurosci. Lett. 115:1990;81-85.
9. Double K., Riederer P., Gerlach M. The significance of neuromelanin in Parkinson's disease. Drug News Dev. 12:1999;333-340.
10. Double K.L., Gerlach M., Youdim M.B.H., Riederer P. Impaired iron homeostatsis in Parkinson's disease. Riederer P., Calne D.B., Horowski R., Mizuno Y. Advances in Research on Neurodegeneration. 8:2000;37-58 Springer, Vienna.
11. Double K.L., Riederer P., Gerlach M. Significance of neuromelanin for neurodegeneration in Parkinson's disease. Drug News Perspect. 12:1999;333-340.
12. Double K.L., Zecca L., Costi P., Mauer M., Griesinger C., Ito S., Ben-Shachar D., Bringman G., Fariello R.G., Riederer P., Gerlach M. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J. Neurochem. 75:2000;2583-2589.
13. Fearnley J., Lees A. Ageing and Parkinson's disease substantia nigra regional selectivity. Brain. 114:1991;2283-2301.
14. 2 and 6-hydroxydopamine. Mov. Disord. 13:1998;661-667.
15. Gerlach M., Ben-Shachar D., Riederer P., Youdim M. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
16. Gerlach M., Double K.L., Youdim M.B.H., Riederer P. Strategies for the protection of dopaminergic neurons against neurotoxicity. Neurotox. Res. 2:2000;99-114.
17. Gerlach M., Riederer P. Animal models of Parkinson's disease an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103:1996;987-1041.
18. Gille G., Rausch W.D., Hung S.T., Moldzio R., Ngyuen A., Janetsky B., Engfer A., Reichmann H. Protection of dopaminergic neurons in primary culture by lisuride. J. Neural Transm. 109:2002;157-169.
19. Good P., Olanow C., Perl D. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease a LAMMA study. Brain Res. 593:1992;343-346.
20. Hall E., Andrus P., Oostveen J., Althaus J., Vonvoigtlander P. Neuroprotective effects of the dopamine D-2/D-3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742:1996;80-88.
21. Halliday G., McRitchie D., Cartwright H., Pamphlett R., Hely M., Morris J. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J. Clin. Neurosci. 3:1996;52-60.
22. Jellinger K. The role of iron in neurodegeneration. Prospects for pharmacotherapy of Parkinson's disease. Drugs Aging. 14:1999;115-140.
23. Jellinger K., Kienzel E., Rumpelmair G., Riederer P., Stachellberger H., Ben-Shachar D., Youdim M.B.H. Iron-melanin complex in substantia nigra of Parkinsonian brains an x-ray microanalysis. J. Neurochem. 59:1992;1168-1171.
24. Kitamura Y., Kohno Y., Nakazawa M., Momura T. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn. J. Pharmacol. 74:1997;51-57.
25. Koller W.C. Levodopa in the treatment of Parkinson's disease. Neurology. 55:(Suppl. 4):2000;8-12.
26. Montastruc J., Rascol O., Senard J. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov. Disord. 14:1999;725-730.
27. 18F)dopa PET. J. Neurol. Neurosurg. Psychiatry. 64:1998;314-319.
28. O'Neill M., Hicks C., Ward M., Cardwell G., Reymann J., Allain H., Bentue-Ferrer D. Dopamine D2 receptor agonists protect against ischemia-induced hippocampal neurodegeneration in global cerebral ischemia. Eur. J. Pharmacol. 352:1998;37-46.
29. Oorschot D. Total number of neurons in the neostriatal, palidal, subthalamic, and substantia nigral nuclei of the rat basel ganglia a stereological study using the Cavalieri and optical disector methods. J. Comp. Neurol. 366:1996;580-599.
30. Opacka-Juffry J., Wilson A., Blunt S. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res. 810:1998;27-33.
31. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1982;Academic Press, New York.
32. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Eng. J. Med. 342:2000;1484-1492.
33. Riederer P., Sian J., Gerlach M. Is there neuroprotection in Parkinson syndrome? J. Neurol. 247:2000;8-11.
34. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J. Neural Transm. 38:1976;277-301.
35. Rinne U. Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy. Nervenarzt. 70:1999;19-25.
36. Sengstock G.J., Olanow C.W., Dunn A.J., Barone S. Jr., Arendash G.W. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behaviour following iron infusion into the rat substantia nigra. Exp. Neurol. 130:1994;82-94.
37. Sengstock G.J., Olanow C.W., Menzies R.A., Dunn A.J., Arendash G.W. Infusion of iron into the rat substantia nigra nigral pathology and dose-dependent loss of striatal dopaminergic markers. J. Neurosci. Res. 35:1993;67-82.
38. Sengstock G.J., Zawia N.H., Olanow C.W., Dunn A.J., Arendash G.W. Intranigral iron infusion in the rat. Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration. Biolog. Trace Element Res. 58:1997;177-195.
39. Wachtel H. Antiparkinsonian dopamine agonists a review of the pharmacokinetics and neuropharmacology in animals and humans. J. Neural Transm. (P-D Sect). 3:1991;151-201.
40. Wooten G.F. Agonists vs levodopa in PD the thrilla of whitha. Neurology. 60:2003;360-362.
41. Xiao A., Double K., Heinemann T., Rausch W.-D., Riederer P., Gerlach M. The industrial chemical Tinuvin 123 does not induce dopaminergic neurotoxicity in C57B1/6 mice. Neurosci. Lett. 278:2000;165-168.
42. Yoshioka M., Tanaka K., Miyazaki I., Fujita N., Higashi Y., Asanuma M., Ogawa N. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavengering free radicals. Neurosci. Res. 43:2002;259-267.
43. Zecca L., Swartz H.M. Total and paramagnetic metals in human substantia nigra and its neuromelanin. J. Neural Transm. (P-D Sect). 5:1993;203-213.